Last reviewed · How we verify
NCT03322072: GPS
Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating
NA trial testing Real-Time Position Transponder Beacons in Lung Cancer Stage I in 28 participants. Status unknown.
14 January 2025
Quick facts
| Lead sponsor | CancerCare Manitoba |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 23 November 2017 |
| Primary completion | 14 January 2025 |
| Estimated completion | 14 January 2025 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- Real-Time Position Transponder Beacons
Conditions studied
- Lung Cancer Stage I — all drugs for Lung Cancer Stage I →
- Lung Cancer Stage II — all drugs for Lung Cancer Stage II →
- Lung Cancer, Nonsmall Cell — all drugs for Lung Cancer, Nonsmall Cell →
- Lung Cancer Recurrent — all drugs for Lung Cancer Recurrent →
Sponsor
CancerCare Manitoba — full company profile →
Who can join
Adults 18 to 85, any sex, with Lung Cancer Stage I or Lung Cancer Stage II. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single arm seamless phase I/II prospective cohort study. Patients with early stage Non-Small Cell Lung Cancer (T1-T2N0M0) or those with a single pulmonary metastasis of a known malignancy (either following radical treatment or systemic therapy) will be offered participation in this study. Participants will have three tumor locator beacons placed with a flexible bronchoscope in the small bronchial airways in proximity (\<3cm) from their lung tumors. These tumor locator beacons will provide real-time positional data and will allow for smaller treatment volumes of Stereotactic Ablative Radiosurgery (SABR) and also allow for a specialized form of treatment delivery known as respiratory gated SABR. This is expected to result in higher precision radiotheapy delivery with less radiotherapy dose to healthy tissues which are in close proximity to the lung tumours.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Endobronchially Implanted Real-Time Electromagnetic Transponder Beacon-Guided, Respiratory-Gated SABR for Moving Lung Tumors: A Prospective Phase 1/2 Cohort Study.
Cheng JC, Buduhan G, Venkataraman S, Tan L, et al · · 2023 · cited 1× · PMID 37408673 · DOI 10.1016/j.adro.2023.101243
Verify or expand the search:
- PubMed search for NCT03322072
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer Stage I
Currently open trials in the same condition.
- NCT06424327 — A Registry for People With Lung Cancer · recruiting
- NCT05832112 — Outside the Cage (OTC) Robotic Lobectomy · NA · active not recruiting
- NCT05281237 — Avecure Flexible Microwave Ablation Probe For Lung Nodules · NA · recruiting
Other CancerCare Manitoba trials
Trials by the same sponsor.
- NCT07460726 — PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Fu · not yet recruiting
- NCT01976962 — Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer · NA · terminated
- NCT03131011 — Body-image Satisfaction Following Permanent Black or Invisible UV Ink Tattoos · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03322072 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CancerCare Manitoba
- Last refreshed: 20 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03322072.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing